dermatology therapeutics

QTORIN Rapamycin Meets Phase 3 Endpoint in MLM

WAYNE, Pa., Feb. 24, 2026 — Palvella Therapeutics announced positive topline results from its Phase 3 SELVA clinical study...

By cGxPwire Editor
February 24, 2026

.VC

Veradermics Closes Full IPO Share Option Exercise

NEW HAVEN, Conn., Feb. 5, 2026 — Veradermics, Incorporated, a late clinical-stage biopharmaceutical company focused on dermatology therapeutics, announced...

By cGxPwire Editor
February 6, 2026

Bio-Pharma

Emrosi™ Trial Shows No Microbiome Impact in Healthy Adults

SCOTTSDALE, Ariz., Dec. 10, 2025 — Journey Medical Corporation announced the publication of Phase 1 clinical trial results evaluating...

By cGxPwire Editor
December 11, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

dermatology therapeutics

QTORIN Rapamycin Meets Phase 3 Endpoint in MLM

Veradermics Closes Full IPO Share Option Exercise

Emrosi™ Trial Shows No Microbiome Impact in Healthy Adults